25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Carisma Therapeutics Inc.
Buy, Hold or Sell?

Let's analyze Carisma Therapeutics Inc. together

I guess you are interested in Carisma Therapeutics Inc.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Carisma Therapeutics Inc.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Carisma Therapeutics Inc.

I send you an email if I find something interesting about Carisma Therapeutics Inc..

1. Quick Overview

1.1. Quick analysis of Carisma Therapeutics Inc. (30 sec.)










1.2. What can you expect buying and holding a share of Carisma Therapeutics Inc.? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.27
Expected worth in 1 year
$-1.64
How sure are you?
30.8%

+ What do you gain per year?

Total Gains per Share
$-1.38
Return On Investment
-162.7%

For what price can you sell your share?

Current Price per Share
$0.85
Expected price per share
$0.8 - $0.96
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Carisma Therapeutics Inc. (5 min.)




Live pricePrice per Share (EOD)
$0.85
Intrinsic Value Per Share
$-24.86 - $-15.61
Total Value Per Share
$-25.12 - $-15.88

2.2. Growth of Carisma Therapeutics Inc. (5 min.)




Is Carisma Therapeutics Inc. growing?

Current yearPrevious yearGrowGrow %
How rich?-$11.1m$89.3m-$82.6m-1,240.0%

How much money is Carisma Therapeutics Inc. making?

Current yearPrevious yearGrowGrow %
Making money-$15.9m-$13.4m-$2.5m-16.0%
Net Profit Margin-386.0%-386.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Carisma Therapeutics Inc. (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Carisma Therapeutics Inc.?

Welcome investor! Carisma Therapeutics Inc.'s management wants to use your money to grow the business. In return you get a share of Carisma Therapeutics Inc..

First you should know what it really means to hold a share of Carisma Therapeutics Inc.. And how you can make/lose money.

Speculation

The Price per Share of Carisma Therapeutics Inc. is $0.8452. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Carisma Therapeutics Inc..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Carisma Therapeutics Inc., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.27. Based on the TTM, the Book Value Change Per Share is $-0.34 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.71 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Carisma Therapeutics Inc..

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.30-36.0%-0.38-45.2%-0.47-55.2%-0.29-34.0%-0.25-30.1%
Usd Book Value Change Per Share-0.28-32.6%-0.34-40.7%-0.71-84.1%-0.02-1.9%-0.02-2.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.28-32.6%-0.34-40.7%-0.71-84.1%-0.02-1.9%-0.02-2.9%
Usd Price Per Share0.98-1.93-4.18-2.01-2.35-
Price to Earnings Ratio-0.81--1.23--2.17--0.92--2.11-
Price-to-Total Gains Ratio-3.57--5.46--8.27--2.15--2.71-
Price to Book Ratio-3.68-46.48-2.74-0.55-2.77-
Price-to-Total Gains Ratio-3.57--5.46--8.27--2.15--2.71-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.8452
Number of shares1183
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.34-0.02
Usd Total Gains Per Share-0.34-0.02
Gains per Quarter (1183 shares)-406.78-19.26
Gains per Year (1183 shares)-1,627.12-77.03
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1627-16370-77-87
20-3254-32640-154-164
30-4881-48910-231-241
40-6508-65180-308-318
50-8136-81450-385-395
60-9763-97720-462-472
70-11390-113990-539-549
80-13017-130260-616-626
90-14644-146530-693-703
100-16271-162800-770-780

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%4.035.00.010.3%4.043.00.08.5%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%7.013.00.035.0%12.027.00.030.8%15.030.02.031.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.039.00.0%0.00.047.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%7.013.00.035.0%12.027.00.030.8%15.030.02.031.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Carisma Therapeutics Inc. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.275-0.344+25%-0.711+158%-0.016-94%-0.025-91%
Book Value Per Share---0.2660.160-267%2.139-112%1.114-124%0.915-129%
Current Ratio--3.2334.044-20%6.791-52%7.018-54%6.975-54%
Debt To Asset Ratio--1.2650.954+33%0.483+162%0.740+71%0.650+95%
Debt To Equity Ratio---42.995-100%0.958-100%10.263-100%7.257-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.304-0.382+26%-0.466+53%-0.288-5%-0.255-16%
Free Cash Flow Per Share---0.687-0.503-27%-0.379-45%-0.303-56%-0.216-69%
Free Cash Flow To Equity Per Share---2.287-0.894-61%-0.007-100%-0.004-100%0.008-28480%
Gross Profit Margin--1.0001.028-3%1.0000%1.006-1%1.0030%
Intrinsic Value_10Y_max---15.610--------
Intrinsic Value_10Y_min---24.856--------
Intrinsic Value_1Y_max---0.968--------
Intrinsic Value_1Y_min---1.442--------
Intrinsic Value_3Y_max---3.364--------
Intrinsic Value_3Y_min---5.266--------
Intrinsic Value_5Y_max---6.307--------
Intrinsic Value_5Y_min---10.084--------
Market Cap35287184.520-16%40981898.16080385642.540-49%174405823.988-77%83809150.740-51%97959651.300-58%
Net Profit Margin---3.752-3.860+3%-3.869+3%-75045004.188+1999900224%-38484626.724+1025590055%
Operating Margin----1.7530%-5.3920%-73480003.9000%-37682061.8510%
Operating Ratio--4.8835.032-3%7.353-34%44930004.678-100%23041037.243-100%
Pb Ratio-3.172+14%-3.68346.476-108%2.742-234%0.546-775%2.770-233%
Pe Ratio-0.695+14%-0.807-1.234+53%-2.169+169%-0.924+15%-2.114+162%
Price Per Share0.845-16%0.9821.925-49%4.177-77%2.007-51%2.346-58%
Price To Free Cash Flow Ratio-0.307+14%-0.357-1.057+196%-1.380+287%-1.144+220%-2.479+594%
Price To Total Gains Ratio-3.072+14%-3.568-5.460+53%-8.269+132%-2.150-40%-2.708-24%
Quick Ratio--2.5462.444+4%8.691-71%7.193-65%6.980-64%
Return On Assets---0.302-0.245-19%-0.116-62%-0.102-66%-0.133-56%
Return On Equity----8.3840%-0.2420%-1.8860%-1.3220%
Total Gains Per Share---0.275-0.344+25%-0.711+158%-0.016-94%-0.025-91%
Usd Book Value---11126000.0006665250.000-267%89315750.000-112%46527900.000-124%38203076.923-129%
Usd Book Value Change Per Share---0.275-0.344+25%-0.711+158%-0.016-94%-0.025-91%
Usd Book Value Per Share---0.2660.160-267%2.139-112%1.114-124%0.915-129%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.304-0.382+26%-0.466+53%-0.288-5%-0.255-16%
Usd Free Cash Flow---28700000.000-21006500.000-27%-15822250.000-45%-12657750.000-56%-9038666.667-69%
Usd Free Cash Flow Per Share---0.687-0.503-27%-0.379-45%-0.303-56%-0.216-69%
Usd Free Cash Flow To Equity Per Share---2.287-0.894-61%-0.007-100%-0.004-100%0.008-28480%
Usd Market Cap35287184.520-16%40981898.16080385642.540-49%174405823.988-77%83809150.740-51%97959651.300-58%
Usd Price Per Share0.845-16%0.9821.925-49%4.177-77%2.007-51%2.346-58%
Usd Profit---12702000.000-15950000.000+26%-13402750.000+6%-10801100.000-15%-10005358.974-21%
Usd Revenue--3385000.0005067000.000-33%3590250.000-6%3925600.001-14%2827769.231+20%
Usd Total Gains Per Share---0.275-0.344+25%-0.711+158%-0.016-94%-0.025-91%
 EOD+2 -6MRQTTM+14 -18YOY+13 -185Y+5 -2710Y+6 -26

3.3 Fundamental Score

Let's check the fundamental score of Carisma Therapeutics Inc. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.695
Price to Book Ratio (EOD)Between0-1-3.172
Net Profit Margin (MRQ)Greater than0-3.752
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.546
Current Ratio (MRQ)Greater than13.233
Debt to Asset Ratio (MRQ)Less than11.265
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.302
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Carisma Therapeutics Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.455
Ma 20Greater thanMa 500.960
Ma 50Greater thanMa 1000.966
Ma 100Greater thanMa 2001.021
OpenGreater thanClose0.833
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Carisma Therapeutics Inc.

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Fundamental data was last updated by Penke on 2024-11-20 22:21:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Carisma Therapeutics Inc. earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Carisma Therapeutics Inc. to the Biotechnology industry mean.
  • A Net Profit Margin of -375.2% means that $-3.75 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Carisma Therapeutics Inc.:

  • The MRQ is -375.2%. The company is making a huge loss. -2
  • The TTM is -386.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-375.2%TTM-386.0%+10.7%
TTM-386.0%YOY-386.9%+0.9%
TTM-386.0%5Y-7,504,500,418.8%+7,504,500,032.8%
5Y-7,504,500,418.8%10Y-3,848,462,672.4%-3,656,037,746.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-375.2%-115.9%-259.3%
TTM-386.0%-210.8%-175.2%
YOY-386.9%-214.5%-172.4%
5Y-7,504,500,418.8%-342.2%-7,504,500,076.6%
10Y-3,848,462,672.4%-464.5%-3,848,462,207.9%
4.3.1.2. Return on Assets

Shows how efficient Carisma Therapeutics Inc. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Carisma Therapeutics Inc. to the Biotechnology industry mean.
  • -30.2% Return on Assets means that Carisma Therapeutics Inc. generated $-0.30 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Carisma Therapeutics Inc.:

  • The MRQ is -30.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -24.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.2%TTM-24.5%-5.7%
TTM-24.5%YOY-11.6%-13.0%
TTM-24.5%5Y-10.2%-14.3%
5Y-10.2%10Y-13.3%+3.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.2%-11.1%-19.1%
TTM-24.5%-11.7%-12.8%
YOY-11.6%-11.3%-0.3%
5Y-10.2%-12.7%+2.5%
10Y-13.3%-14.3%+1.0%
4.3.1.3. Return on Equity

Shows how efficient Carisma Therapeutics Inc. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Carisma Therapeutics Inc. to the Biotechnology industry mean.
  • 0.0% Return on Equity means Carisma Therapeutics Inc. generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Carisma Therapeutics Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-838.4%+838.4%
TTM-838.4%YOY-24.2%-814.2%
TTM-838.4%5Y-188.6%-649.8%
5Y-188.6%10Y-132.2%-56.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.2%+14.2%
TTM-838.4%-15.8%-822.6%
YOY-24.2%-13.9%-10.3%
5Y-188.6%-18.5%-170.1%
10Y-132.2%-19.5%-112.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Carisma Therapeutics Inc..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Carisma Therapeutics Inc. is operating .

  • Measures how much profit Carisma Therapeutics Inc. makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Carisma Therapeutics Inc. to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Carisma Therapeutics Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-175.3%+175.3%
TTM-175.3%YOY-539.2%+363.9%
TTM-175.3%5Y-7,348,000,390.0%+7,348,000,214.7%
5Y-7,348,000,390.0%10Y-3,768,206,185.1%-3,579,794,204.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--258.6%+258.6%
TTM-175.3%-318.3%+143.0%
YOY-539.2%-224.0%-315.2%
5Y-7,348,000,390.0%-386.5%-7,348,000,003.5%
10Y-3,768,206,185.1%-497.6%-3,768,205,687.5%
4.3.2.2. Operating Ratio

Measures how efficient Carisma Therapeutics Inc. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 4.88 means that the operating costs are $4.88 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Carisma Therapeutics Inc.:

  • The MRQ is 4.883. The company is inefficient in keeping operating costs low. -1
  • The TTM is 5.032. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.883TTM5.032-0.149
TTM5.032YOY7.353-2.321
TTM5.0325Y44,930,004.678-44,929,999.646
5Y44,930,004.67810Y23,041,037.243+21,888,967.435
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8832.594+2.289
TTM5.0323.360+1.672
YOY7.3533.299+4.054
5Y44,930,004.6784.788+44,929,999.890
10Y23,041,037.2436.528+23,041,030.715
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Carisma Therapeutics Inc..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Carisma Therapeutics Inc. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.23 means the company has $3.23 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Carisma Therapeutics Inc.:

  • The MRQ is 3.233. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.044. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.233TTM4.044-0.811
TTM4.044YOY6.791-2.747
TTM4.0445Y7.018-2.974
5Y7.01810Y6.975+0.044
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2333.658-0.425
TTM4.0443.874+0.170
YOY6.7914.672+2.119
5Y7.0185.960+1.058
10Y6.9756.277+0.698
4.4.3.2. Quick Ratio

Measures if Carisma Therapeutics Inc. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Carisma Therapeutics Inc. to the Biotechnology industry mean.
  • A Quick Ratio of 2.55 means the company can pay off $2.55 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Carisma Therapeutics Inc.:

  • The MRQ is 2.546. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.444. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.546TTM2.444+0.102
TTM2.444YOY8.691-6.247
TTM2.4445Y7.193-4.748
5Y7.19310Y6.980+0.212
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5463.104-0.558
TTM2.4443.426-0.982
YOY8.6914.498+4.193
5Y7.1935.933+1.260
10Y6.9806.426+0.554
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Carisma Therapeutics Inc..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Carisma Therapeutics Inc. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Carisma Therapeutics Inc. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.26 means that Carisma Therapeutics Inc. assets are financed with 126.5% credit (debt) and the remaining percentage (100% - 126.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Carisma Therapeutics Inc.:

  • The MRQ is 1.265. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 0.954. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ1.265TTM0.954+0.311
TTM0.954YOY0.483+0.471
TTM0.9545Y0.740+0.214
5Y0.74010Y0.650+0.090
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2650.354+0.911
TTM0.9540.345+0.609
YOY0.4830.311+0.172
5Y0.7400.366+0.374
10Y0.6500.382+0.268
4.5.4.2. Debt to Equity Ratio

Measures if Carisma Therapeutics Inc. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Carisma Therapeutics Inc. to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Carisma Therapeutics Inc.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM42.995-42.995
TTM42.995YOY0.958+42.037
TTM42.9955Y10.263+32.731
5Y10.26310Y7.257+3.006
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.398-0.398
TTM42.9950.437+42.558
YOY0.9580.378+0.580
5Y10.2630.452+9.811
10Y7.2570.495+6.762
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Carisma Therapeutics Inc. generates.

  • Above 15 is considered overpriced but always compare Carisma Therapeutics Inc. to the Biotechnology industry mean.
  • A PE ratio of -0.81 means the investor is paying $-0.81 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Carisma Therapeutics Inc.:

  • The EOD is -0.695. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.807. Based on the earnings, the company is expensive. -2
  • The TTM is -1.234. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.695MRQ-0.807+0.112
MRQ-0.807TTM-1.234+0.427
TTM-1.234YOY-2.169+0.935
TTM-1.2345Y-0.924-0.310
5Y-0.92410Y-2.114+1.190
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.695-2.160+1.465
MRQ-0.807-2.428+1.621
TTM-1.234-3.145+1.911
YOY-2.169-3.304+1.135
5Y-0.924-6.080+5.156
10Y-2.114-6.625+4.511
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Carisma Therapeutics Inc.:

  • The EOD is -0.307. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.357. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.057. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.307MRQ-0.357+0.050
MRQ-0.357TTM-1.057+0.700
TTM-1.057YOY-1.380+0.324
TTM-1.0575Y-1.144+0.087
5Y-1.14410Y-2.479+1.335
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.307-2.980+2.673
MRQ-0.357-3.295+2.938
TTM-1.057-3.682+2.625
YOY-1.380-4.523+3.143
5Y-1.144-8.162+7.018
10Y-2.479-9.239+6.760
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Carisma Therapeutics Inc. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -3.68 means the investor is paying $-3.68 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Carisma Therapeutics Inc.:

  • The EOD is -3.172. Based on the equity, the company is expensive. -2
  • The MRQ is -3.683. Based on the equity, the company is expensive. -2
  • The TTM is 46.476. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.172MRQ-3.683+0.512
MRQ-3.683TTM46.476-50.159
TTM46.476YOY2.742+43.734
TTM46.4765Y0.546+45.930
5Y0.54610Y2.770-2.224
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.1721.869-5.041
MRQ-3.6832.027-5.710
TTM46.4762.365+44.111
YOY2.7422.419+0.323
5Y0.5463.668-3.122
10Y2.7704.362-1.592
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Carisma Therapeutics Inc..

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Total Stockholder Equity 46,298-19,76626,532-15,63710,895-10,535360-11,486-11,126



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets42,058
Total Liabilities53,184
Total Stockholder Equity-11,126
 As reported
Total Liabilities 53,184
Total Stockholder Equity+ -11,126
Total Assets = 42,058

Assets

Total Assets42,058
Total Current Assets34,137
Long-term Assets7,921
Total Current Assets
Cash And Cash Equivalents 26,881
Other Current Assets 7,256
Total Current Assets  (as reported)34,137
Total Current Assets  (calculated)34,137
+/-0
Long-term Assets
Property Plant Equipment 7,713
Long-term Assets Other 208
Long-term Assets  (as reported)7,921
Long-term Assets  (calculated)7,921
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities10,558
Long-term Liabilities42,626
Total Stockholder Equity-11,126
Total Current Liabilities
Short-term Debt 2,460
Accounts payable 1,728
Other Current Liabilities 5,688
Total Current Liabilities  (as reported)10,558
Total Current Liabilities  (calculated)9,876
+/- 682
Long-term Liabilities
Long-term Liabilities  (as reported)42,626
Long-term Liabilities  (calculated)0
+/- 42,626
Total Stockholder Equity
Common Stock41
Retained Earnings -287,944
Other Stockholders Equity 276,777
Total Stockholder Equity (as reported)-11,126
Total Stockholder Equity (calculated)-11,126
+/-0
Other
Cash and Short Term Investments 26,881
Common Stock Shares Outstanding 41,544
Current Deferred Revenue682
Liabilities and Stockholders Equity 42,058
Net Debt -23,564
Net Working Capital 23,579
Short Long Term Debt Total 3,317



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
9,503
0
0
14,081
11,237
55,227
46,824
36,981
55,000
46,578
55,122
47,603
36,825
14,333
9,267
79,578
104,097
99,068
95,048
72,268
75,097
123,713
119,295
111,561
105,439
127,612
119,398
114,365
104,665
101,213
109,028
122,823
186,414
241,047
235,671
35,449
225,840
97,358
199,724
271,627
156,132
133,013
106,784
89,554
73,795
59,339
42,058
42,05859,33973,79589,554106,784133,013156,132271,627199,72497,358225,84035,449235,671241,047186,414122,823109,028101,213104,665114,365119,398127,612105,439111,561119,295123,71375,09772,26895,04899,068104,09779,5789,26714,33336,82547,60355,12246,57855,00036,98146,82455,22711,23714,081009,503
   > Total Current Assets 
8,271
0
0
13,194
8,030
54,407
46,033
36,291
54,401
46,138
54,432
47,015
36,311
13,806
8,834
31,812
25,927
20,980
16,458
12,108
14,981
63,767
59,385
51,756
45,451
67,529
59,412
54,447
44,883
41,468
49,041
62,867
126,579
175,099
200,480
29,786
180,637
84,163
192,358
189,144
144,502
122,200
97,565
80,471
60,953
50,721
34,137
34,13750,72160,95380,47197,565122,200144,502189,144192,35884,163180,63729,786200,480175,099126,57962,86749,04141,46844,88354,44759,41267,52945,45151,75659,38563,76714,98112,10816,45820,98025,92731,8128,83413,80636,31147,01554,43246,13854,40136,29146,03354,4078,03013,194008,271
       Cash And Cash Equivalents 
7,882
0
0
12,911
7,942
53,964
45,031
35,943
54,059
45,549
53,494
46,362
36,079
13,419
8,484
30,716
25,342
20,268
15,751
11,338
14,680
62,961
57,856
50,422
42,437
64,931
57,865
48,121
42,463
37,741
41,969
52,389
109,965
151,036
175,236
28,551
169,790
39,698
71,107
133,553
62,777
76,353
83,132
77,605
56,515
40,362
26,881
26,88140,36256,51577,60583,13276,35362,777133,55371,10739,698169,79028,551175,236151,036109,96552,38941,96937,74142,46348,12157,86564,93142,43750,42257,85662,96114,68011,33815,75120,26825,34230,7168,48413,41936,07946,36253,49445,54954,05935,94345,03153,9647,94212,911007,882
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
41,906
106,427
54,366
76,190
40,725
11,005
0
1,548
1,548
0
01,5481,548011,00540,72576,19054,366106,42741,9060000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,886
2,303
1,107
24,493
2,052
14,119
14,297
825
0
0
0
0
0
2,000
0
02,0000000082514,29714,1192,05224,4931,1072,3032,886000000000000000050000000000000000
       Other Current Assets 
389
0
0
283
88
443
1,002
348
342
589
938
653
232
387
350
1,046
585
712
707
770
301
806
1,529
1,334
3,014
2,598
1,547
6,326
2,420
3,727
7,072
10,478
13,728
21,760
24,137
1,235
8,795
757
527
400
5,535
5,122
3,428
2,866
4,438
9,084
7,256
7,2569,0844,4382,8663,4285,1225,5354005277578,7951,23524,13721,76013,72810,4787,0723,7272,4206,3261,5472,5983,0141,3341,5298063017707077125851,0463503872326539385893423481,0024438828300389
   > Long-term Assets 
1,232
0
0
887
3,207
820
791
690
599
440
690
588
514
527
433
47,766
78,170
78,088
78,590
60,160
60,116
59,946
59,910
59,805
59,988
60,083
59,986
59,918
59,782
59,745
59,987
59,956
59,835
65,948
35,191
5,663
45,203
13,195
7,366
82,483
11,630
10,813
9,219
9,083
12,842
8,618
7,921
7,9218,61812,8429,0839,21910,81311,63082,4837,36613,19545,2035,66335,19165,94859,83559,95659,98759,74559,78259,91859,98660,08359,98859,80559,91059,94660,11660,16078,59078,08878,17047,7664335275145886904405996907918203,207887001,232
       Property Plant Equipment 
1,197
0
0
862
759
708
682
585
486
422
580
480
407
353
314
894
796
714
632
585
522
421
365
321
272
376
294
238
207
185
154
123
93
109
53
5,663
33
13,195
14,798
13,450
11,600
10,637
9,043
8,937
12,700
8,476
7,713
7,7138,47612,7008,9379,04310,63711,60013,45014,79813,195335,6635310993123154185207238294376272321365421522585632714796894314353407480580422486585682708759862001,197
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,312
16,864
16,864
17,371
13,064
13,064
13,064
13,064
13,064
13,064
13,064
13,064
13,064
13,064
13,064
13,064
13,064
13,064
13,064
13,064
13,064
13,064
0
0
0
0
0
0
0
0
0
0
000000000013,06413,06413,06413,06413,06413,06413,06413,06413,06413,06413,06413,06413,06413,06413,06413,06413,06413,06417,37116,86416,86410,312000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
36,200
60,500
60,500
60,500
46,400
46,400
46,400
46,400
46,400
46,400
46,400
46,400
46,400
46,400
46,400
46,400
46,400
46,400
46,400
14,700
14,700
14,700
0
0
0
0
0
0
0
0
0
0
000000000014,70014,70014,70046,40046,40046,40046,40046,40046,40046,40046,40046,40046,40046,40046,40046,40046,40046,40060,50060,50060,50036,200000000000000000
       Long-term Assets Other 
35
0
0
25
2,448
112
109
105
113
18
110
108
107
174
119
360
10
10
87
111
130
61
81
20
252
243
228
216
111
96
369
369
278
6,375
7,374
-27,764
17,406
-19,641
-14,798
4,111
30
146
146
0
142
142
208
2081421420146146304,111-14,798-19,64117,406-27,7647,3746,37527836936996111216228243252208161130111871010360119174107108110181131051091122,448250035
> Total Liabilities 
3,764
0
0
7,553
8,891
9,000
8,201
8,203
18,174
15,612
17,903
18,938
17,881
2,363
3,094
38,133
65,420
66,163
69,138
55,202
57,063
59,649
68,900
67,354
67,379
112,243
116,931
141,065
86,214
103,841
125,581
132,050
177,144
191,698
74,663
9,425
53,043
97,544
34,695
113,437
70,062
66,308
60,486
63,022
62,900
58,979
53,184
53,18458,97962,90063,02260,48666,30870,062113,43734,69597,54453,0439,42574,663191,698177,144132,050125,581103,84186,214141,065116,931112,24367,37967,35468,90059,64957,06355,20269,13866,16365,42038,1333,0942,36317,88118,93817,90315,61218,1748,2038,2019,0008,8917,553003,764
   > Total Current Liabilities 
1,825
0
0
3,711
5,353
6,303
6,027
6,507
5,202
4,642
5,472
7,607
7,580
2,282
3,008
6,265
3,980
3,226
3,855
4,404
4,720
4,533
6,561
6,113
7,053
7,948
9,092
8,517
7,366
6,513
9,708
18,049
17,367
18,827
12,594
7,691
8,474
13,159
34,695
30,984
21,477
17,973
12,951
15,908
13,141
15,617
10,558
10,55815,61713,14115,90812,95117,97321,47730,98434,69513,1598,4747,69112,59418,82717,36718,0499,7086,5137,3668,5179,0927,9487,0536,1136,5614,5334,7204,4043,8553,2263,9806,2653,0082,2827,5807,6075,4724,6425,2026,5076,0276,3035,3533,711001,825
       Short-term Debt 
0
0
0
0
0
1,642
1,642
1,642
251
1,010
2,523
3,711
4,134
0
0
697
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
898
0
4,857
33,175
0
3,785
3,701
1,388
0
3,864
4,924
2,460
2,4604,9243,86401,3883,7013,785033,1754,85708980000000000000000000697004,1343,7112,5231,0102511,6421,6421,64200000
       Accounts payable 
1,107
0
0
670
1,746
3,070
2,602
2,588
2,458
2,043
1,880
2,279
1,246
1,588
1,855
1,761
1,667
1,214
1,245
1,366
907
1,310
1,391
1,367
1,683
2,176
2,583
1,902
2,068
1,274
1,524
3,102
2,004
1,228
3,909
2,322
666
3,868
514
1,233
4,614
2,487
2,409
3,933
2,166
2,033
1,728
1,7282,0332,1663,9332,4092,4874,6141,2335143,8686662,3223,9091,2282,0043,1021,5241,2742,0681,9022,5832,1761,6831,3671,3911,3109071,3661,2451,2141,6671,7611,8551,5881,2462,2791,8802,0432,4582,5882,6023,0701,746670001,107
       Other Current Liabilities 
718
0
0
1,925
2,492
457
1,140
1,656
1,987
1,327
618
1,146
1,794
491
1,153
2,557
1,888
2,012
2,610
3,038
3,813
3,223
5,170
4,746
5,370
5,772
6,509
6,615
5,298
5,239
8,184
13,447
13,863
16,099
8,685
4,471
7,808
3,987
34,181
29,751
10,942
10,369
7,969
965
5,922
8,001
5,688
5,6888,0015,9229657,96910,36910,94229,75134,1813,9877,8084,4718,68516,09913,86313,4478,1845,2395,2986,6156,5095,7725,3704,7465,1703,2233,8133,0382,6102,0121,8882,5571,1534911,7941,1466181,3271,9871,6561,1404572,4921,92500718
   > Long-term Liabilities 
1,939
0
0
3,842
3,538
2,697
2,174
1,696
12,972
10,970
12,431
11,331
10,301
81
86
31,868
61,440
62,937
65,283
50,798
52,343
55,116
62,339
61,241
60,326
104,295
107,839
132,548
78,848
97,328
115,873
114,001
159,777
172,871
62,069
1,734
44,569
84,385
52,202
82,453
48,585
48,335
47,535
47,114
49,759
43,362
42,626
42,62643,36249,75947,11447,53548,33548,58582,45352,20284,38544,5691,73462,069172,871159,777114,001115,87397,32878,848132,548107,839104,29560,32661,24162,33955,11652,34350,79865,28362,93761,44031,868868110,30111,33112,43110,97012,9721,6962,1742,6973,5383,842001,939
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50,496
0
0
46,809
0
0
0
0
0
0000046,8090050,49600000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
146
0
0
0
0
0
0000014600000000000000000000000000000000000000000
> Total Stockholder Equity
5,739
0
0
6,528
2,346
46,227
38,623
28,778
36,826
30,966
37,219
28,665
18,944
11,970
6,173
41,445
38,677
32,905
25,910
17,066
18,034
64,064
50,395
44,207
38,060
15,369
2,467
-26,700
18,451
-2,628
-16,553
-9,227
9,270
49,349
161,008
11,629
172,797
-14,581
165,029
158,190
86,070
66,705
46,298
26,532
10,895
360
-11,126
-11,12636010,89526,53246,29866,70586,070158,190165,029-14,581172,79711,629161,00849,3499,270-9,227-16,553-2,62818,451-26,7002,46715,36938,06044,20750,39564,06418,03417,06625,91032,90538,67741,4456,17311,97018,94428,66537,21930,96636,82628,77838,62346,2272,3466,528005,739
   Common Stock
1
0
0
10
2
16
16
16
18
18
19
20
20
20
20
24
25
25
25
25
35
77
77
77
77
101
101
107
110
116
123
140
172
188
199
199
199
199
202
202
40
40
40
0
41
41
41
41414104040402022021991991991991881721401231161101071011017777777735252525252420202020191818161616210001
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
-899
0
0
-1,234
-1,337
0
0
0
-1,747
0
0
0
-1,957
0
0
0
-71
0
0
0
-331
0
0
-539
0
0
-4,519
-758
-789
-820
-850
0
-911
0
0
0
0
-197
-235
-546
136
265
373
0
0
0
0
0000373265136-546-235-1970000-9110-850-820-789-758-4,51900-53900-331000-71000-1,957000-1,747000-1,337-1,23400-899
   Capital Surplus 00000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000
   Other Stockholders Equity 
1,171
0
0
60,486
4,597
111,027
111,544
112,373
130,305
129,222
142,380
143,518
146,083
144,726
145,420
161,201
162,034
162,243
162,564
162,825
170,661
229,239
229,585
230,693
230,487
262,107
266,856
267,475
271,090
276,380
285,086
306,554
381,442
446,036
486,010
619
489,662
766
385,821
386,867
268,759
269,141
270,029
0
274,934
275,561
276,777
276,777275,561274,9340270,029269,141268,759386,867385,821766489,662619486,010446,036381,442306,554285,086276,380271,090267,475266,856262,107230,487230,693229,585229,239170,661162,825162,564162,243162,034161,201145,420144,726146,083143,518142,380129,222130,305112,373111,544111,0274,59760,486001,171



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue14,919
Cost of Revenue-74,125
Gross Profit-59,206-59,206
 
Operating Income (+$)
Gross Profit-59,206
Operating Expense-103,650
Operating Income-88,731-162,856
 
Operating Expense (+$)
Research Development74,125
Selling General Administrative29,525
Selling And Marketing Expenses8,265
Operating Expense103,650111,915
 
Net Interest Income (+$)
Interest Income1,936
Interest Expense-1,936
Other Finance Cost-1,936
Net Interest Income1,936
 
Pretax Income (+$)
Operating Income-88,731
Net Interest Income1,936
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-86,879-90,583
EBIT - interestExpense = -90,667
-78,782
-84,943
Interest Expense1,936
Earnings Before Interest and Taxes (EBIT)-88,731-84,943
Earnings Before Interest and Taxes (EBITDA)-85,894
 
After tax Income (+$)
Income Before Tax-86,879
Tax Provision-0
Net Income From Continuing Ops-86,879-86,879
Net Income-86,879
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses103,650
Total Other Income/Expenses Net1,852-1,936
 

Technical Analysis of Carisma Therapeutics Inc.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Carisma Therapeutics Inc.. The general trend of Carisma Therapeutics Inc. is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Carisma Therapeutics Inc.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Carisma Therapeutics Inc..

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.8752 < 0.8752 < 0.96.

The bearish price targets are: 0.8.

Tweet this
Carisma Therapeutics Inc. Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Carisma Therapeutics Inc.. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Carisma Therapeutics Inc. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Carisma Therapeutics Inc.. The current macd is -0.04118447.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Carisma Therapeutics Inc. price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Carisma Therapeutics Inc.. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Carisma Therapeutics Inc. price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Carisma Therapeutics Inc. Daily Moving Average Convergence/Divergence (MACD) ChartCarisma Therapeutics Inc. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Carisma Therapeutics Inc.. The current adx is 19.35.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Carisma Therapeutics Inc. shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Carisma Therapeutics Inc. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Carisma Therapeutics Inc.. The current sar is 0.9437405.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Carisma Therapeutics Inc. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Carisma Therapeutics Inc.. The current rsi is 33.45. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Carisma Therapeutics Inc. Daily Relative Strength Index (RSI) ChartCarisma Therapeutics Inc. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Carisma Therapeutics Inc.. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Carisma Therapeutics Inc. price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Carisma Therapeutics Inc. Daily Stochastic Oscillator ChartCarisma Therapeutics Inc. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Carisma Therapeutics Inc.. The current cci is -104.5361954.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Carisma Therapeutics Inc. Daily Commodity Channel Index (CCI) ChartCarisma Therapeutics Inc. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Carisma Therapeutics Inc.. The current cmo is -42.16124565.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Carisma Therapeutics Inc. Daily Chande Momentum Oscillator (CMO) ChartCarisma Therapeutics Inc. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Carisma Therapeutics Inc.. The current willr is -91.87096774.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Carisma Therapeutics Inc. Daily Williams %R ChartCarisma Therapeutics Inc. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Carisma Therapeutics Inc..

Carisma Therapeutics Inc. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Carisma Therapeutics Inc.. The current atr is 0.05510369.

Carisma Therapeutics Inc. Daily Average True Range (ATR) ChartCarisma Therapeutics Inc. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Carisma Therapeutics Inc.. The current obv is 17,813,890.

Carisma Therapeutics Inc. Daily On-Balance Volume (OBV) ChartCarisma Therapeutics Inc. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Carisma Therapeutics Inc.. The current mfi is 22.38.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Carisma Therapeutics Inc. Daily Money Flow Index (MFI) ChartCarisma Therapeutics Inc. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Carisma Therapeutics Inc..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-07-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-07-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-02BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-08-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-08-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-02MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-08STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-09STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-10-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-25WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-11-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-07ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Carisma Therapeutics Inc. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Carisma Therapeutics Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.455
Ma 20Greater thanMa 500.960
Ma 50Greater thanMa 1000.966
Ma 100Greater thanMa 2001.021
OpenGreater thanClose0.833
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Carisma Therapeutics Inc. with someone you think should read this too:
  • Are you bullish or bearish on Carisma Therapeutics Inc.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Carisma Therapeutics Inc.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Carisma Therapeutics Inc.

I send you an email if I find something interesting about Carisma Therapeutics Inc..


Comments

How you think about this?

Leave a comment

Stay informed about Carisma Therapeutics Inc..

Receive notifications about Carisma Therapeutics Inc. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.